Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Freed

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
The American Journal of Bioethics : AJOB|July 2, 2016
IRB and Research Regulatory Delays Within the Military Health System: Do They Really Matter? And If So, Why and for Whom?Michael C Freed, Laura A Novak, William D S Killgore, et al.
NPJ Vaccines|June 3, 2021
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trialLeike Li, Daniel C Freed, Yaping Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 26, 1998
Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administrationD H Barouch, S Santra, T D Steenbeke, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 19, 1997
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccinationN L Letvin, D C Montefiori, Y Yasutomi, et al.
Structure (London, England : 1993)|June 9, 2015
GTP-Dependent K-Ras DimerizationSerena Muratcioglu, Tanmay S Chavan, Benjamin C Freed, et al.
The Journal of Infectious Diseases|October 8, 2020
Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus VaccineKara S Cox, Lu Zhang, Daniel C Freed, et al.
NPJ Vaccines|December 22, 2017
Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccinationFengsheng Li, Daniel C Freed, Aimin Tang, et al.
Antimicrobial Agents and Chemotherapy|December 28, 2020
Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human CytomegalovirusHang Su, Xiaohua Ye, Daniel C Freed, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSFDan H Barouch, Sampa Santra, Klara Tenner-Racz, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
The American Journal of Bioethics : AJOB|July 2, 2016
IRB and Research Regulatory Delays Within the Military Health System: Do They Really Matter? And If So, Why and for Whom?Michael C Freed, Laura A Novak, William D S Killgore, et al.
NPJ Vaccines|June 3, 2021
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trialLeike Li, Daniel C Freed, Yaping Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 26, 1998
Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administrationD H Barouch, S Santra, T D Steenbeke, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 19, 1997
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccinationN L Letvin, D C Montefiori, Y Yasutomi, et al.
Structure (London, England : 1993)|June 9, 2015
GTP-Dependent K-Ras DimerizationSerena Muratcioglu, Tanmay S Chavan, Benjamin C Freed, et al.
The Journal of Infectious Diseases|October 8, 2020
Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus VaccineKara S Cox, Lu Zhang, Daniel C Freed, et al.
NPJ Vaccines|December 22, 2017
Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccinationFengsheng Li, Daniel C Freed, Aimin Tang, et al.
Antimicrobial Agents and Chemotherapy|December 28, 2020
Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human CytomegalovirusHang Su, Xiaohua Ye, Daniel C Freed, et al.
AIDS Research and Human Retroviruses|December 7, 2006
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjectsTimothy W Tobery, Sheri A Dubey, Kiersten Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSFDan H Barouch, Sampa Santra, Klara Tenner-Racz, et al.
Pageof 13